Want to see HK:2186 full AI Analyst Report?
2186 Stock Chart & Stats
HK$2.14
-HK$0.03(-1.44%)
At close: 4:00 PM EDT
HK$2.14
-HK$0.03(-1.44%)
Day’s Range― - ―
52-Week RangeHK$1.69 - HK$3.69
Previous CloseN/A
Volume25.36M
Average Volume (3M)34.21M
Market Cap
HK$6.88B
Enterprise ValueHK$8.58K
Total Cash (Recent Filing)HK$13.33B
Total Debt (Recent Filing)HK$12.54B
Price to Earnings (P/E)9.3
Beta0.91
Next Earnings
Mar 31, 2027EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.66%
Share Statistics
EPS (TTM)0.17
Shares Outstanding3,994,515,900
10 Day Avg. Volume27,232,832
30 Day Avg. Volume34,214,287
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.68Price Target Upside25.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$6.14B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHigh gross, EBIT, and EBITDA margins indicate meaningful operating profitability and suggest the branded-pharmaceutical portfolio retains pricing and product economics. If sustained, this margin base can fund research, commercialization, and balance-sheet strengthening across the next several quarters.
Improving LeverageThe reduction in debt-to-equity materially improves financial flexibility compared with earlier years. A less leveraged balance sheet can reduce funding pressure, support continued investment in the pipeline, and provide greater resilience if product demand or industry conditions weaken.
Cash Flow ReboundThe return to positive operating and free cash flow shows that the business restored cash generation in 2025 after a difficult prior year. This supports internally funded operations and investment, although sustained performance will be important to establish lasting cash-conversion strength.
Bears Say
Sharp Revenue ContractionA steep revenue decline raises concerns about the durability of demand and the stability of the company’s current profit base. Even with strong margins, a smaller commercial base can reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on a narrower portfolio.
Volatile Free Cash FlowLarge swings in free cash flow reduce confidence that reported earnings consistently translate into deployable cash. This variability can complicate research spending, product launches, and capital allocation, while the history of negative periods leaves less certainty around the durability of shareholder cash returns.
Low Return On EquityLow return on equity indicates that the enlarged equity base is generating limited bottom-line efficiency. Unless profitability improves relative to invested capital, the company may struggle to compound shareholder value efficiently even while maintaining healthy operating margins and manageable leverage.
Luye Pharma Group News
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$1.69 and its highest was HK$3.69 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is HK$6.88B.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 190 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Aug 30, 2026. The company reported HK$0.03 earnings per share for the quarter, missing the consensus estimate of HK$0.058 by -HK$0.028.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of 2.66%. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.03 in its last earnings report, missing expectations of HK$0.058. Following the earnings report the stock price went up 3.719%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
2186 Stock 12 Month Forecast
Average Price Target
HK$2.68
▲(25.08% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―